A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
about
Rivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseSystematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsEvidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's DiseaseTreatment guidelines for Alzheimer's disease: redefining perceptions in primary care.A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Donepezil in severe Alzheimer's disease.Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.[Cross-cultural adaptation of the Disability Assessment for Dementia (DAD)].
P2860
Q24186551-6C17A8B3-6D8F-4113-9B15-2CA0BD96FBADQ24187067-AF436817-5810-49B2-B240-0C89AE069FF3Q24241686-257A5546-42F9-4A0B-B2B2-0AF8EDE01BF1Q26863383-F8CC42A9-A48D-4906-8A65-A7152DB81244Q28212725-DEFD9164-2E63-4A0B-9091-787B5863E271Q30443975-F4585A8E-E989-49B3-9E36-0F31AE23A8A2Q34521949-818B593F-F896-4587-898F-A51AD3F3242DQ34629649-AAC949B8-AB33-409E-AEDE-2BD0818F03AEQ37358548-3C64C627-E6BC-41A1-BCB5-1A1115C1F383Q37396299-24C11C4F-196F-4B0D-95B0-8533B292DA1CQ37402181-035EF59E-ACE7-4BF9-8C17-5B746681B39EQ46804778-3D2EA99E-A8DA-4AC5-84D7-2EF326C2CC21Q46897348-CDD12F24-D10C-4B60-AC80-43CEC47D25ABQ51963515-5B4EFEC1-4447-45AB-AF09-50877DEFC9C6Q53029167-45D0CE9F-CC25-49A2-B55A-2B671573A7DE
P2860
A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A 12-month study of the effica ...... moderate Alzheimer's disease.
@en
A 12-month study of the effica ...... moderate Alzheimer's disease.
@nl
type
label
A 12-month study of the effica ...... moderate Alzheimer's disease.
@en
A 12-month study of the effica ...... moderate Alzheimer's disease.
@nl
prefLabel
A 12-month study of the effica ...... moderate Alzheimer's disease.
@en
A 12-month study of the effica ...... moderate Alzheimer's disease.
@nl
P2093
P2860
P356
P1476
A 12-month study of the effica ...... moderate Alzheimer's disease.
@en
P2093
Ali Ozdemir Ersoy
Emel Köseoğlu
Füsun Erdoğan
Tayfun Turan
Yahya Karaman
P2860
P356
10.1159/000080972
P577
2004-09-21T00:00:00Z